<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279135</url>
  </required_header>
  <id_info>
    <org_study_id>Project 803</org_study_id>
    <nct_id>NCT01279135</nct_id>
  </id_info>
  <brief_title>Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix</brief_title>
  <acronym>PARCER</acronym>
  <official_title>Phase III Randomized Trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for Late Toxicity Reduction After Postoperative Radiotherapy in Ca Cervix.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study tests Tomtherapy based Image Guided Radiation against conventional radiation
      techniques for it's ability to reduce long term small bowel toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Late Grade II-IV bowel toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify small bowel dose volume characteristics that predict for Grade II-IV late toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify preoperative functional imaging features that predict for local recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life between Tomotherapy vs conventional radiotherapy</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cancer Cervix</condition>
  <arm_group>
    <arm_group_label>Conventional RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive conventional radiation with or without chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tomotherapy based IGRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Radiation</intervention_name>
    <description>Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks</description>
    <arm_group_label>Conventional RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tomotherapy based IGRT</intervention_name>
    <description>Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks</description>
    <arm_group_label>Tomotherapy based IGRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathological diagnosis of carcinoma cervix with postoperative intermediate or
             high risk features.

          -  Age &gt;18 years.

          -  Planned for Wertheim's hysterectomy or has already undergone Wertheim's hysterectomy
             OR has undergone Simple Hysterectomy with no evidence of residual nodes on MRI/PET
             imaging+/- confirmatory nodal biopsy.

          -  No evidence of paraaortic nodal metastasis.

        Exclusion Criteria:

          -  History of multiple previous abdominal surgeries placing patient at baseline high risk
             of bowel toxicity or any other medical condition with baseline bowel movement
             disorder.

          -  Rectal Polyps or extensive hemorrhoids.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supriya Chopra, MD,DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Supriya Chopra, MD, DNB</last_name>
    <phone>02227405000</phone>
    <phone_ext>5510</phone_ext>
    <email>schopra@actrec.gov.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>410210</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supriya Chopra, MD,DNB</last_name>
      <phone>022-27405000</phone>
      <phone_ext>5510</phone_ext>
      <email>schopra@actrec.gov.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Supriya Chopra</name_title>
    <organization>Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre</organization>
  </responsible_party>
  <keyword>IGRT,Postoperative, Cervix, Late toxicity, Bowel</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

